Skip to main content
. Author manuscript; available in PMC: 2012 Feb 5.
Published in final edited form as: JAMA. 2009 Jul 22;302(4):412–423. doi: 10.1001/jama.2009.1063

Table 1.

Characteristics of 36 Prospective Studies Contributing Data to the Current Analysis

No. of Events
Sourcea Participants,
No./Male, No.		 Age at
Survey,
Mean
(SD), y		 Lp(a), Median
(IQR), mg/dL		 Median
Follow-up
(5th-95th
Percentile)		 Nonfatal
MI/GHD
Death		 CHD
Death		 Nonfatal
MI		 Fatal
MI		 Fatal/Nonfatal Stroke
 Non-
CVD
Death
Ische-
mic		 Hemor-
rhagic		 Unclas-
sified
Cohort Studies
AFTCAPS42C 902/745 59 (7.1) 7.6 (3.3-17.9) 5.7 (4.5-6.8) 21 1 20 1 3 0 0 7
ARIC,20 2001 14033/6087 54 (5.7) 18.3 (6.9-43.8) 14.1 (5.0-15.7) 850 190 660 114 431 52 16 947
ATTICA21C 1508/777 51 (11.1) 11.4 (4.9-25.2) 5.0 (5.0-5.0) 0 0 0 0 0 0 0 16
BRUN,22 1999 798/385 58 (11.4) 88 (4.4-21.6) 15.3 (3.9-15.5) 53 31 22 19 24 14 0 120
CHARL24C 165/165 70 (7.5) 10.4 (3.4-22.3) 6.3 (1.2-7.5) 19 3 16 2 0 2 7 15
CHS 1,23 2003 3860/1480 72 (5.2) 12.6 (4.8-22.2) 12.1 (2.0-12.9) 592 212 380 212 367 62 36 797
COPEN,16 2008 7487/3144 59 (13.6) 19.1 (6.9-42.6) 7.4 (2.4-8.9) 283 36 247 0 184 39 94 525
DUBBO,25 2002 2008/842 68 (6.7) 11.0 (5.0-27.8) 14.1 (1.8-14.9) 273 56 217 0 73 19 81 315
EAS,26 2001 637/323 64 (5.6) 92 (3.7-25.4) 15.1 (2.3-15.6) 54 25 29 18 0 2 34 123
FINRISK 92,27 2005 2201/1022 54 (62) 12.2 (4.5-31.7) 11.8 (4.4-11.9) 92 21 71 10 45 18 0 114
FRAMOFF,28 1996 2850/1316 54 (9.8) 16.7 (7.1-36.6) 12.0 (5.7-14.4) 109 12 97 0 52 6 0 182
GOH29C 638/307 71 (6.7) 17.5 (10.0-37.0) 3.9 (0.3-6.9) 0 0 0 0 0 0 0 0
GRIPS,30 1997 5784/5784 48 (5.1) 9.0 (4.0-25.0) 9.8 (4.3-10.0) 299 0 299 0 0 0 103 158
KIHD31C 1996/1996 53 (5.3) 9.6 (3.8-22.1) 19.2 (2.9-23.1) 386 11 375 6 104 34 3 239
NHANES 332C 4496/1923 54 (15.7) 23.0 (9.0-46.0) 7.5 (3.9-9.0) 107 107 0 38 0 0 46 321
NPHS II,33 2001 2375/2375 57 (3.4) 10.9 (4.3-29.3) 8.3 (3.5-10.4) 157 13 139 16 23 7 17 97
PRIME,34 2002 7441/7441 55 (2.9) 10.0 (5.0-30.0) 5.2 (5.0-7.3) 115 13 102 10 24 3 3 92
PROCAM,35 1996 3198/2255 43 (10.4) 4.0 (2:0-13.0) 17.4 (5.3-18.6) 94 23 71 3 12 4 2 98
QUEBEC,36 1998 2012/2012 56 (6.9) 19.0 (7.8-47.3) 5.3 (4.3-5.6) 53 5 48 4 0 0 9 45
SHS,37 2002 3837/1515 56 (8.0) 3.0 (1.1-6.7) 12.5 (2.1-14.3) 416 133 283 62 8 8 177 750
TARFS38C 1400/667 54 (10.5) 10.1 (4.2-21.6) 2.2 (1.2-4.5) 3 3 0 3 0 0 3 12
ULSAM39C 1866/1866 51 (4.5) 8.3 (3.4-22.3) 27.1 (5.9-35.8) 485 124 361 60 164 42 30 457
WHITE 240C 7903/5467 49 (6.0) 21.0 (12.0-46.0) 7.6 (3.8-8.2) 170 23 147 18 1 0 3 86
WHS,15 2006 27 791/0 55 (7.1) 10.6 (4.4-32.8) 10.2 (8.4-10.8) 227 10 217 4 229 25 1 540
WOSCOPS,43 2000 4617/4617 55 (5.6) 17.0 (7.0-50.0) 5.0 (2.8-6.0) 299 60 239 0 0 0 61 83
ZUTE41C 305/305 75 (4.5) 12.3 (5.8-28.7) 9.1 (1.1-10.1) 42 13 29 9 1 1 25 65
Subtotal 112 108/54 816 55 (9.5) 12.9 (5.0-32.7) 9.7 (3.6-15.7) 5199 1130 4069 614 1750 338 751 6204
Nested Case-Control Studies (Individually Matched)
BUPA,44 1994 1505/1505 53 (7.2) 19.2 (8.7-47.7) 23.7 (4.5-26.9) 208 208 0 170 0 0 0 173
FIA,45 1998 1492/1073 55 (7.6) 26.5 (11.8-45.0) 3.7 (0.5-8.6) 519 118 401 118 0 0 0 0
FLETCHER,45 2007 689/541 57 (14.3) 20.7 (7.2-59.5) 5.6 (2.2-6.4) 140 NA NA 0 0 0 0 0
HPFS47C 726/726 63 (8.3) 13.0 (5.6-37.3) 7.7 (3.0-8.5) 220 35 185 9 0 0 0 18
MRFIT,48 2001 736/736 47 (5.6) 3.4 (1.2-9.3) 7.1 (6.0-73) 246 19 227 13 0 0 0 5
NHS,49 2005 705/0 60 (6.5) 9.5 (43-23.2) 8.0 (1.4-8.8) 234 27 207 27 0 0 0 10
Subtotal 5353/4581 55 (9.6) 16.0 (5.5-40.5) 7.0 (1.3-25.9) 1567 407b 1020b 337 0 0 0 206
Nested Case-Control Studies (Frequency-Matched)
BRHS50C 1561/1561 52 (5.3) 6.5 (3.4-16.6) 20.3 (3.7-23.6) 461 169 292 122 0 0 0 221
GOTO 33,51 1993 128/128 51 (0.2) 10.2 (4.2-32.0) 12.8 (1.7-13.1) 16 7 9 4 0 0 0 7
REYK,10 2008 6179/4359 55 (9.0) 9.3 (2.9-22.8) 20.3 (3.3-33.5) 1850 810 1040 228 0 0 0 1476
USPHS,52 1993 805/805 60 (9.0) 9.5 (3.8-24.1) NA 243 22 221 22 153 0 0 0
Subtotal 8673/6853 55 (8.6) 3.7 (3.2-21.8) 20.1 (3.4-32.9) 2570 1008 1562 376 153 0 0 1704
Total 126 634/65 755 55 (9.4) 12.6 (4.9-32.1) 9.3 (3.5-21.3) 9336 2545b 6651b 1327 1903 338 751 8114

Abbreviations: CHD, coronary heart disease; IQR, interquartile range; Lp(a), lipoprotein(a); MI, myocardial infarction; MA, data not available; non-CVD, nonvascular.

a

eAppendix 3 lists the study acronyms.

b

Numbers sum to less than the total of CHD events because 1 study46 did not provide seperate data on CHD death and nonfatal MI.

c

Studies that had not previously published their findings on LP(a) and vascular risk.